← Back to Screener
BioVie Inc. Warrant (BIVIW)
Price$0.32
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-38.47%
Price vs S&P 500 (4W)21.41%
VGM Score67.55
All Metrics
Price vs S&P 500 (YTD)20.16%
10-Day Avg Trading Volume0.01M
3-Month Avg Trading Volume0.01M
52-Week High$0.52
26-Week Price Return-24.89%
13-Week Price Return4.00%
3-Month Return Std Dev206.35%
Year-to-Date Return31.47%
5-Day Price Return9.74%
Month-to-Date Return-3.43%
Price vs S&P 500 (13W)-6.66%
52-Week Low$0.17
mGradeB
vgmGradeB
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BIVIWBioVie Inc. Warrant | — | — | B | $0.32 |
| LLYEli Lilly & Co. | D | B | B | $1078.78 |
| JNJJohnson & Johnson | C | C | C | $223.24 |
| ABBVABBVIE INC. | D | C | C | $217.13 |
| MRKMerck & Co., Inc. | C | C | C | $114.70 |
| AZNAstraZeneca PLC | D | B | C | $176.28 |
| NVSNovartis AG | C | C | C | $143.66 |
| NVONovo-Nordisk A/S | B | B | B | $42.00 |
| ABTAbbott Laboratories | C | C | D | $86.99 |
| PFEPfizer Inc. | B | C | C | $25.34 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $32.83 |
About
BioVie Inc is a clinical-stage biopharmaceutical company developing drug therapies for chronic debilitating conditions including liver disease, neurological and neuro-degenerative disorders, and certain cancers. The company is advancing NE3107 through a Phase 3 clinical trial for mild to moderate Alzheimer's disease. BIV201 is being developed to address life-threatening complications of liver cirrhosis caused by hepatitis, non-alcoholic steatohepatitis, and alcoholism.